Trade with Eva: Analytics in action >>

Thursday, March 8, 2018

=Audentes Therapeutics (BOLD) reported earnings on Thur 8 March 2018 (a/h)



Audentes Therapeutics reports Q4 results, provides clinical update 
  • Reports Q4 (Dec) loss of $0.82 per share, $0.09 better than the Capital IQ Consensus of ($0.91). Co has no revenue.
  • "Among our many accomplishments, we are particularly pleased to have recently reported positive interim data from the first dose cohort of patients in ASPIRO, the Phase 1/2 clinical study of our product candidate AT132 to treat XLMTM. These promising initial data add to the growing body of evidence of the utility of AAV-based gene therapy to treat rare neuromuscular diseases, and we are optimistic that they signal a turning point in our ability to bring meaningful benefit to patients and families living with XLMTM."
  • "As we look forward to the year ahead, we are excited by our many anticipated upcoming pipeline catalysts, including sharing additional data from our ASPIRO study in XLMTM, new data from our VALENS study in Crigler-Najjar, and advancing additional product candidates into the clinic for Pompe disease and CASQ2-CPVT. With our recently completed follow-on offering, we are well capitalized to continue our mission to develop transformative gene therapy products for patients living with serious, life-threatening rare diseases."

No comments:

Post a Comment